A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma

Atsushi Hagihara; Yuga Teranishi; Etsushi Kawamura; Hideki Fujii; Shuji Iwai; Hiroyasu Morikawa; Masaru Enomoto; Akihiro Tamori; Norifumi Kawada

doi:10.2169/internalmedicine.52.9340

CASE REPORTS

A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma

Atsushi Hagihara, Yuga Teranishi, Etsushi Kawamura, Hideki Fujii, Shuji Iwai, Hiroyasu Morikawa, Masaru Enomoto, Akihiro Tamori, Norifumi Kawada

Author information

Atsushi Hagihara
Department of Hepatology, Osaka City University Hospital, Japan
Yuga Teranishi
Department of Hepatology, Osaka City University Hospital, Japan
Etsushi Kawamura
Department of Hepatology, Osaka City University Hospital, Japan
Hideki Fujii
Department of Hepatology, Osaka City University Hospital, Japan
Shuji Iwai
Department of Hepatology, Osaka City University Hospital, Japan
Hiroyasu Morikawa
Department of Hepatology, Osaka City University Hospital, Japan
Masaru Enomoto
Department of Hepatology, Osaka City University Hospital, Japan
Akihiro Tamori
Department of Hepatology, Osaka City University Hospital, Japan
Norifumi Kawada
Department of Hepatology, Osaka City University Hospital, Japan

Keywords: sorafenib, complete response, hepatocellular carcinoma

JOURNAL OPEN ACCESS

2013 Volume 52 Issue 14 Pages 1589-1592

DOI https://doi.org/10.2169/internalmedicine.52.9340

Details

Abstract

The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.

Corresponding author

Register with J-STAGE for free!